Increased chromosomal instability that alters the gene copy numbers throughout the genome is known to have a role in molecular pathogenesis of tumors. The impact of gene dosage effect to the expression levels of genes in GIST and LMS is unknown. In this paper, we used a combination of array comparative genomic hybridization (aCGH) and gene expression data to gain insights into the interplay of structural and functional changes of the genome in GIST and LMSs. We identified specific target genes that change their expression due to the gene dosage effect. Statistical analysis identified four chromosomal regions, 1p, 14q, 15q, and 22q, where both copy number and mRNA expression were significantly different between the tumor types. Multi-dimensional scaling (MDS) analysis showed that the gene expression profiles of these four regions accurately distinguish GIST and LMS. In addition, the gene dosage sensitive genes in these regions are differently involved in several tumor growth promoting pathways, implying that there are different mechanisms underlying the GIST and LMS carcinogenesis. Integration of aCGH and gene expression data has not only provided insights into how DNA copy number variations affect the gene expression patterns in these cancers, but also proves to be a promising method to choose biologically relevant biomarkers.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and are typically characterized by specific KIT or PDGFRA mutations. In addition to KIT or PDGFRA mutations, other genetic and epigenetic events are likely involved in the tumorigenesis. Previously reported cytogenetic aberrations include loss of 1p, 13q, 14q, 15q, LOH of 22q (1) (2) (3) . More specific aberrations include LOH of p16(INK4A) or p14(ARF), homozygous loss of Hox11L1, amplification of C-MYC, MDM2, EGFR1, CCND1 and others (4-6).
Leiomyosarcoma (LMS) is a malignant tumor composed of cells showing distinct features of the smooth muscle lineage and constitutes a significant percentage of retroperitoneal and pelvic sarcomas (7) . The great majority of leiomyosarcomas are reactive for smooth muscle actin (SMA), desmin, and h-caldesmon on immunohistochemistry, though none of these markers are absolutely specific for smooth muscle differentiation. The cytogenetic aberrations in LMS are complex Technology in Cancer Research & Treatment, Volume 9, Number 2, April 2010 at 1q21, 5p14-pter, 8q, 12q13-15, 13q31, 17p11, 19p13, and 20q13 (8-11) .
Historically, GISTs were often histologically classified as leiomyosarcoma because of their morphological similarities and anatomic location. These tumors, however, warrant with frequent chromosomal gains of 1q21, 1p3, 5p15, 6q, 8q24, 16p, 17p, 17q, 19, 20q, 22q, and Xp, 1p36, 2p, 2q, 4q, 9p, 10p, 11p, 16q, and 18p11 . In addition, high-level amplification were identified Figure 1 : Computational karyotyping reveals differential copy number alterations (CNAs) (A) and expression (B) in GIST and LMS. (A) The differential CNAs between GIST and LMS. Value on y-axis is the negative log10 transformed significance. X-axis represents genes sequentially aligned on chromosomes with the chromosome numbers indicated. The significance was calculated by using Fisher's exact test on frequency of gains (positive axis) and losses (negative axis). Dashed line indicates the threshold (P<0.01) for a significant CNA. Red color denotes significantly differential amplification and green color significantly differential deletion. Gray color represents non-significant difference between GIST and LMS. Note that for 1p, 14q and 15q, sequences in these region are more frequently amplified in LMS (red bar) and more frequently deleted in GIST (green bar), which is consistent with their expression. (B) The differential gene expression regions between GIST and LMS. Value on y-axis denotes the degree of differential expression between GIST and LMS for each chromosome position on x-axis. Horizontal dashed line indicates the threshold (P<0.05). Scores that exceed this threshold are colored to emphasize the locations of differential expression. Red color denotes significant over-expression in GIST and green color denotes significant under-expression in GIST. Gray color represents non-significantly differential expression between LMS and GIST.
(4×44k) (Agilent Technologies, Palo Alto, CA). These arrays have over 43,000 coding and non-coding human sequences represented, yielding an average of 35kbp oligonucleotide probe spatial resolution. In addition, transcriptomes of 68 primary tumors (37 GISTs and 31 LMSs) were measured on Agilent whole human genome oligo arrays with 60-mer probes (Agilent Technologies, Palo Alto, CA). These arrays have over 40,000 probes representing more than 18,000 genes. Both aCGH and gene expression data were obtained from 14,415 genes from 32 GISTs and 25 LMSs.
Array CGH Data Analysis
Intensity values were first lowess-normalized to compensate for common non-linear biases. Ratios of normalized intensity values from tumor tissues and normal tissue were then transformed to log 2 -space. The log ratio were further subjected to the circular binary segmentation (CBS) algorithm (14) to reduce the effect of noise. This algorithm splits the log ratio data into segments representing genomic regions of equal copy number. CGHcall algorithm (15) was further used to label segments of constant copy number as gain or loss. The aCGH data will be deposited to the public database.
Gene Expression Data Analysis
The log 2 -transformed and quantile normalized expression profiles are available at http://www3.mdanderson. org/~genomics/sarcoma_data_matrix_for_supplemental.zip. The probe with the highest average expression was chosen to represent each gene. SAM algorithm (16) was applied for identification of differentially expressed genes (DEGs). MACAT (17) algorithm was then applied to provide a smooth estimate of differential expression over chromosomal coordinate window (10e5 base pairs per window).
Statistical Analyses
To identify the differentially aberrated genes between GIST and LMS, we first applied Fisher's exact test to compare the frequencies of genes copy number change in GIST and LMS samples. Where after, false discovery rates (FDR) were computed from the p-values (18) to account for the resulting multiple hypothesis testing problem. Genes with FDR<0.1 were considered to have a significant copy number change between GIST and LMS.
To reveal the influence of gene dosage alteration to transcript levels within each tumor type, we used CGHcall algorithm to assign each gene: g for gain, l for loss, and n for normal copy number, so that each gene's expression can be categorized into groups according their statuses. ANOVA was further applied to assess the difference of expression between different groups and thus revealing influence of dosage alteration accurate diagnosis because of their distinctly different therapeutic approaches. Specifically, in sharp contrast to the estimated 80% of patients with GIST who benefit from imatinib, patients with LMS do not gain any benefit from this agent. On the other hand, the treatment of GIST patients with chemotherapy results in a less than 10% objective response rate whereas greater than 50% of LMS patients respond to traditional cytotoxic chemotherapy (12) . (13) performed bacterial artificial chromosomes (BAC)-based comparative genomic hybridization arrays (aCGH) on 7 GISTs and 12 LMSs and identified six chromosomal regions, 1p36.11-p13. 1, 9q21.11-9q34.3, 14q11.2-q23.2, 14q31.3-q32.33, 15q24.3-q26.3, and 22q11.21-q13.31 , which were significantly different in copy number between GISTs and LMSs. This early study illustrated the potential of using aCGH to classify these two histologically similar tumors. However, early studies have not performed integrative analysis of DNA copy number aberrations (CNAs) and gene expression (GE) changes to determine if the changes in chromosome would lead to resultant changes in the mRNA levels of corresponding genes.
In the present study, we addressed this issue by exploring the difference and the relation of the transcriptomes and the genomes in 32 GISTs and 25 LMSs by performing an integrated analysis of gene expression and copy number aberrations. By integrating paired aCGH and gene expression data, we were able to look into the chromosomal distributions of differentially aberrated genes (DAGs) and differentially expressed genes (DEGs) between GIST and LMS, aiming to identify new candidate genes or chromosome regions for diagnostic purposes and to shed light on the different tumor promoting mechanisms in these cancers.
Our analyses on the genomes and the transcriptomes of the two tumor types revealed four chromosomal regions, 1p, 14q, 15q, and 22q, where both copy number and gene expression were significantly different between these GISTs and LMSs. Multidimensional scaling (MDS) illustrated that the expression of genes in these four particular regions can classify GIST from LMS very accurately. Although we observed a correlation between gene dosage and gene expression in the above four chromosomal regions in both tumor types, the genome-wide relation between gene dosage and expressions was not strong in either type, suggesting that epigenetic regulation may play a significant role in the pathogenesis of these two tumor types.
Methods

Array Measurements and Data Integration
Genomes of 72 primary tumors (42 GISTs and 30 LMSs) were measured on Agilent Human Genome CGH Microarrays Technology in Cancer Research & Treatment, Volume 9, Number 2, April 2010 number and gene expression. A non-metric MDS (Figure 2 ) analysis based on the expression of 1441 genes in these regions reveals that they can potentially act as diagnostic biomarkers that differentiate between GIST and LMS. In addition to that, pathway enrichment on the 358 genes in these regions uncovered the different biological functions between these two types of sarcomas (Figure 3) . Among the cancer related pathways were cell cycle, adherens junctions and focal adhesion, and a number of signaling pathways including TGF-beta signaling.
Discussion
Growing evidence indicates that cancer development and progression are results of the accumulation of specific genetic alterations (21) . Loss of function of tumor suppressor genes or activation of oncogenes (or both) resulting from copy number changes might play important roles in these alterations (22) (23) (24) . On the other hand, the studies on mRNA expression of tumors have demonstrated the impact of expression profiling on cancer prognosis and diagnosis research areas (25-27). These results from single data type have encouraged a need for making integrative analysis of information generated from multiple genomic levels and platforms. This type of integrative analysis is expected to provide more comprehensive insight into how cancer develops and to help identify more robust biomarkers and therapeutic targets.
Towards this goal, we first explored the difference and the relation of transcriptomes and genomes by performing an integrative analysis of gene expression and copy number data from 32 GIST and 25 LMS. By integrating paired genomic for each gene on its transcript. Genes with P < 0.001 were considered significant.
Enrichment analysis was performed to the list of genes, which were both differentially aberrated and expressed. Here we use the gene annotations to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Pathways that get more annotations in our gene list than expected by random (hypergeometric model, P<0.005) were considered to significantly enrich with the interesting genes.
All computational analyses were done using Matlab version R2008b, R version 2.8.1 and Bioconductor software package.
Results
We carried out a joint comparison of the genome and the transcriptome between GIST and LMS to find out what extent of differential expression between these two tumors was due to differential gene copy numbers. For each gene, we applied Fisher's exact test and SAM to compare its aberration frequencies and expression between GIST and LMS. A total of 7214 probes representing 5611 genes were found to have different copy number levels between GIST and LMS (FDR<0.1). The results from these loci are presented in a computational karyotype by mapping each measured sequence evenly in chromosome order on x-axis ( Figure 1A) . We observed that the GISTs had more frequent copy number deletions in multiple chromosome regions including 1p, 2q25,2q31, 6p22-p21.3,6p25, 7p22 -21, 7p15-14, 7q32, 7q34-36, 10q21-q26, 12p13, 14q, 15q, 16q, 22q; whereas LMSs had a higher amplification rate in 1p, 14q and 15q.
In the expression profiles, a total of 4257 probes representing 3075 genes were found differentially expressed between GIST and LMS. Among these probes, 499 out of 2560 significantly under-expressed probes were located in the same chromosomal regions as the frequently different CNAs and 59 out of 1697 significantly over-expressed probes were located in the regions of different CNAs. We applied the MACAT algorithm to generate a comparable computational karyotype from the gene expression data ( Figure 1B) . Significant (p<0.001) gene dosage-gene transcript relationships was observed for 111 (0.7%) and 173 (1.2%) of 14,415 expressed genes in the 32 GIST and 25 LMS tumors, respectively. The highly differentially expressed genes on 1q, 14q, and 15q were notably frequently deleted in GISTs and amplified in most LMS. We further looked into the genes located in 1p, 14q, 15q, and 22q. Of the 1441 genes with copy number changes between GIST and LMS in these regions, 358 show differential expression. This is highly significant (p<10e-6 from hypergeometric test), given the globally poor correlation between gene copy cancers (29). Our integrated study suggests that the difference in adherens junctions and focal adhesion between LMS and GIST is a major molecular mechanism that defines their differential response to chemotherapy.
data, we were able to investigate the difference between aCGH and gene expression pattern between GIST and LMS in general. Statistical analysis revealed four chromosomal regions, 1p, 14q, 15q, and 22q, where both copy number and mRNA expression were concordantly different between two tumor samples. Overall the recurrent gene dosage effect on expression levels was found to affect only a small number of genes. The fact that we observed expression and CNA correlation only in chromosomal regions 1p, 14q, and 15q implies that these regions may contain key genes whose differential expression levels are the most critical for the different phenotypes of these two types of sarcomas. In other words, these genes may represent the "driver genes" among a sea of "passenger genes" that were aberrated. Other confounding factors include epigenetic alteration such as methylation and microRNA expression that may have a significant contribution to the steady-state gene expression levels even in the setting of gene copy number changes. This hypothesis can be tested in the future when methylation and microRNA expression data on the same samples become available.
These "driver gene" may also represent the early biological events that in the specification of these two sarcoma types. Cancer is known to be heterogeneous and many changes can accumulate in subpopulations during the cancer progression. Whereas these later changes in subpopulations would likely have important impact on clinical outcomes such as response to therapy, they do not significantly contribute to the overall difference of the two sarcoma types. An integrated analysis with response to therapy or other clinical parameter as end-point will likely reveal the robust prognostic driver gene events. However, this type of analysis requires data from a large number of cases with clinical follow-up.
Our pathway analysis with the 358 genes in the key chromosomal regions, 1p, 14q, 15q, and 22q uncovered cell cycle, adherens junctions, focal adhesion, and a number of signaling pathways including TGF-beta signaling. It is well established that cell cycle status plays an important role in response of cancer to chemotherapy and most chemotherapeutic agents selectively target cycling cells (19, 28) . For the case of GIST and LMS, the response rate to chemotherapy for GIST is less than 10% whereas the response rate for LMS is greater than 50% (12) . Thus, it is biologically consistent that the most significant difference in our pathway analysis of GIST and LMS is cell cycle. The observation that these two sarcoma types have key difference in adherens junctions and focal adhesion pathway is also consistent with the literature report showing the differential abilities in cell migration of these two type of sarcomas (20) . In cancers, cell adhesion molecules are characteristically dysregulated and these adhesion molecules are critical for cell growth, survival, migration, extravasation, homing, and metastasis. Furthermore, cell adhesion also mediates drug resistance in many
